has function has role vaccinated in route immunizes against disease immunizes recipient cancer Homo sapiens intravenous route therapeutic vaccine function vaccine in clinical trial role therapeutic cancer vaccine whole cell cancer vaccine MT-201-GBM monocyte vaccine NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C179670 cancer vaccine 6315 A cancer vaccine consisting of autologous monocytes loaded with mRNA encoding the human cytomegalovirus (CMV) matrix protein pp65 (65 kDa lower matrix phosphoprotein; UL83) as a fusion protein with the lysosome-associated membrane protein (LAMP), with potential immunostimulatory and antineoplastic activities. The autologous CMV-pp65-LAMP mRNA loaded monocyte vaccine MT-201-GBM exposes the immune system to the CMV pp65 peptide, which may elicit a cytotoxic T-lymphocyte (CTL) response against CMV pp65-expressing tumor cells. The incorporation of LAMP may route CMV pp-65 antigens into the lysosomal compartment, resulting in enhanced MHC class II antigen presentation, thereby promoting CD4-positive T-cell responses. MT-201-GBM (pp65CMV antigen monocytes) are administered to patients newly diagnosed with a type of brain tumor called glioblastoma (GBM) that has an unmethylated MGMT (O[6]-methylguanine-DNA methyltransferase) (MGMT) gene promoter. The vaccine is made from a type of immune cell called monocytes, which have been engineered to express a cytomegalovirus (CMV) protein. Patients also receive standard radiation therapy combined with temozolomide. VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6315 NCT: https://clinicaltrials.gov/study/NCT04741984 Jie Zheng Hayleigh Kahn